We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
Libra Therapeutics is developing novel therapeutics for neurodegenerative diseases BETHESDA, MD (US) and EDINBURGH (UK), September 23, 2020 – Epidarex Capital (“Epidarex”), a transatlantic... ETD002 is a novel TMEM16A chloride channel potentiator Therapy applicable to all cystic fibrosis patients, independent of genotype Brighton, UK, 17 August 2020: Enterprise Therapeutics Ltd (Enterprise...
Epidarex Capital Co-leads $29 Million Series A Financing in Newly Formed Libra Therapeutics
Enterprise Therapeutics doses first subjects in Phase 1 trial for First-in-Class cystic fibrosis therapy ETD002